Oxurion & Bicycle Therapeutics declare full enrollment for DME study
Category: #health  By Nikita Chaurasia  Date: 2019-04-26
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Oxurion & Bicycle Therapeutics declare full enrollment for DME study

Bicycle Therapeutics, a biotech firm pioneering a new therapeutic class based on its patented bicyclic peptide or Bicycle® platform, and Oxurion have recently declared complete registration of Oxurion’s Phase I clinical trial planned to assess the safety of THR-149’s single injection. The injection essentially is a new Bicycle-based plasma kallikrein suppressor.

According to a press release by the Bicycle Therapeutics, the agreement states that Oxurion has exclusive authority to conduct clinical and preclinical development, as well as commercialization of a designated medicine candidate. In return, Bicycle would attain milestone payments for development and royalties on sales of products resulting from the association.

Bicycle provides a differentiated method to a variety of debilitating ailments, and the company is pleased to view the growth Oxurion has attained in successfully finishing the registration of the Phase I study of the first Bicycle-based therapeutic, stated Kevin Lee, Ph.D., CEO Bicycle Therapeutics.

THR-149, in consort with Bicycle-owned BT1718, Bicycle Toxin Conjugate for oncology, represents the first of many initiatives the firm is proceeding with to bring this exceptional therapeutic modality to patients with significant unfulfilled medical needs, Lee added.

Patrik De Haes, M.D. & CEO of Oxurion, reportedly stated that patients suffering from diabetic macular edema have higher levels of PKal. Our aim in the current Phase I clinical trial is to assess the safety of a single THR-149 intravitreal injection, a new Bicycle-based PKal suppressor, in patients having visual impairment because of diabetic macular edema, Haes stated. Enrolling subjects is the first step to assessing whether we can constrain PKal with Bicycle’s new bicyclic peptides, he added.

For the record, Bicycle Therapeutics is a clinical-phase biopharmaceutical firm developing a new class of pills, termed as Bicycles, for illnesses that are underserved by currently available therapeutics. It was founded in 2009, resulting from an innovative science performed by Professor Christian Heinis and Sir Greg Winter.

Source Credits: https://www.apnews.com/Business%20Wire/2aec99859114480da690c30619ccc460

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Nokia partners with LG Uplus to expand 5G coverage in South Korea

Nokia partners with LG Uplus to expand 5G coverage in South Korea

By Nikita Chaurasia

Finnish telecommunications giant Nokia Corporation has reportedly signed a joint venture agreement with LG Uplus, a prominent cellular carrier, to expand 5G coverage in South Korea. The duo intends to achieve this by deploying Nokia’s end-to-e...

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

By Nikita Chaurasia

Mercedes-Benz, a German multinational automaker of luxury and commercial vehicles, has unveiled its flagship electric sedan, the EQS. The new vehicle is likely to allow Mercedes to take on Tesla Inc., as the market for electric vehicles (EVs) continu...

Ford takes on GM, Tesla by debuting its first hands-free driving system

Ford takes on GM, Tesla by debuting its first hands-free driving system

By Nikita Chaurasia

Ford Motor Company, the American multinational automaker, is reportedly planning on introducing a hands-free driving feature on its 2021 Mustang Models as well as 2021 F-150 pickup truck through a software update, by the end of the year. The automob...